AstraZeneca PLC (BVMF:A1ZN34)

Market Cap	1.50T
Revenue (ttm)	309.78B
Net Income (ttm)	50.09B
Shares Out	n/a
EPS (ttm)	32.08
PE Ratio	29.99
Forward PE	18.09
Dividend	1.39 (1.69%)
Ex-Dividend Date	Aug 7, 2025

Volume	97
Average Volume	2,795
Open	81.46
Previous Close	80.65
Day's Range	79.30 - 81.46
52-Week Range	61.90 - 84.71
Beta	0.17
RSI	57.54
Earnings Date	Nov 6, 2025

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, B...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1992
• Employees: 94,300
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: A1ZN34

Financial Performance

In 2024, AstraZeneca's revenue was $54.07 billion, an increase of 18.03% compared to the previous year's $45.81 billion. Earnings were $7.04 billion, an increase of 18.14%.

Financial numbers in USD